A 5-Question Quiz on Breast Cancer

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Muhammed Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Leticia Nogueira, PhD, MPH

Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Considering Dosing and AE Management Strategies With Tarlatamab in SCLC

A phase 2 trial presented at SSO met its primary end point by achieving negative margins in 79% of patients with node-negative rectal cancer.

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP

March 24th 2025

Sirexatamab Combo Shows Positive Activity in Advanced MSS Colorectal Cancer

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.

Russ Conroy

Osimertinib Shows Sustained Survival Benefit in EGFR-Mutant NSCLC

Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.

The safety profiles of osimertinib monotherapy and combination therapy were consistent with prior reports in EGFR-mutated non–small cell lung cancer.

Roman Fabbricatore

March 30th 2025

HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

The safety profiles of osimertinib monotherapy and combination therapy were consistent with prior reports in EGFR-mutated non–small cell lung cancer.

Related Content

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Muhammed Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.

Leticia Nogueira, PhD, MPH

Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Considering Dosing and AE Management Strategies With Tarlatamab in SCLC

A phase 2 trial presented at SSO met its primary end point by achieving negative margins in 79% of patients with node-negative rectal cancer.

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP

March 24th 2025

Sirexatamab Combo Shows Positive Activity in Advanced MSS Colorectal Cancer

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Russ Conroy

Osimertinib Shows Sustained Survival Benefit in EGFR-Mutant NSCLC

Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.

Roman Fabbricatore

March 30th 2025